




Proposed Intergational  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


acidum octanoicum  
octanoic acid

octanoic acid  
 $C_8H_{16}O_2$  124-07-2




alaceprilum  
alacepril

*N*-[1-[(*S*)-3-mercapto-2-methylpropionyl]-*L*-prolyl]-3-phenyl-*L*-alanine acetate  
(ester)  
 $C_{20}H_{26}N_2O_5S$  74258-86-9




almoxatonum  
almoxatone

(+)-(*R*)-3-[*p*-[(*m*-chlorobenzyl)oxy]phenyl]-5-[(methylamino)methyl]-2-oxazolidinone  
 $C_{18}H_{19}ClN_2O_3$  84145-89-1



altanserinum  
altanserin

3-[2-[4-(*p*-fluorobenzoyl)piperidino]ethyl]-2-thio-2,4(1*H*,3*H*)-quinazolin-6(1*H*)-one  
 $C_{22}H_{22}FN_3O_2S$  76330-71-7




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


amflutizolum  
amflutizole

4-amino-3-( $\alpha,\alpha,\alpha$ -trifluoro-*m*-tolyl)-5-isothiazolecarboxylic acid  
C<sub>11</sub>H<sub>7</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S 82114-19-0




amosulalolum  
amosulalol

( $\pm$ )-5-[1-hydroxy-2-[[2-(*o*-methoxyphenoxy)ethyl]amino]ethyl]-*o*-  
toluenesulfonamide  
C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>S 85320-68-9



aptazapinum  
aptazapine

( $\pm$ )-1,3,4,14b-tetrahydro-2-methyl-2*H*,10*H*-pyrazino[1,2-*a*]pyrrolo-  
[2,1-*c*][1,4]benzodiazepine  
C<sub>15</sub>H<sub>19</sub>N<sub>3</sub> 71576-40-4




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


asproxicillinum  
asproxicillin

(2*S*,5*R*,6*R*)-6-[(2*R*)-2-[(2*R*)-2-amino-3-(methylcarbamoyl)propionamido]-2-(*p*-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid  
C<sub>21</sub>H<sub>27</sub>N<sub>5</sub>O<sub>7</sub>S 63358-49-6




avidinum  
avidine

2,2'-[[3-(dioctadecylamino)propyl]imino]diethanol  
C<sub>43</sub>H<sub>90</sub>N<sub>2</sub>O<sub>2</sub> 35607-20-6




benaxibinum  
benaxibine

*p*-(*D*-xylosylamino)benzoic acid  
C<sub>12</sub>H<sub>15</sub>NO<sub>5</sub> 27661-27-4



bencianolum  
bencianol

(2*R*,3*S*)-3',4'-[[diphenylmethylene]dioxy]-3,5,7-flavantriol  
C<sub>28</sub>H<sub>22</sub>O<sub>6</sub> 85443-48-7




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


bunazosinum  
bunazosin

1-(4-amino-6,7-dimethoxy-2-quinazoliny)-4-butyrylhexahydro-1H-1,4-diazepine  
 $C_{19}H_{27}N_5O_3$  80755-51-7




cabastinum  
cabastine

{±}-trans-1-[cis-4-cyano-4-(p-fluorophenyl)cyclohexyl]-3-methyl-4-phenylisonipecotic acid  
 $C_{26}H_{28}FN_2O_2$  79449-98-2



carbetimerum  
carbetimer

maleic anhydride polymer with ethylene, reaction product with ammonia  
82230-03-3




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


carvedilolom  
carvedilol

(±)-1-(carbazol-4-yloxy)-3-[[2-(*o*-methoxyphenoxy)ethyl]amino]-2-propanol  
C<sub>24</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub> 72956-09-3




cefpiimizolum  
cefpiimizole

1-[[[(6*R*,7*R*)-2-carboxy-7-[(*R*)-2-(5-carboxyimidazole-4-carboxamido)-2-phenylacetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-4-(2-sulfoethyl)pyridinium hydroxide, inner salt  
C<sub>28</sub>H<sub>26</sub>N<sub>6</sub>O<sub>10</sub>S<sub>2</sub> 84880-03-5




ceftropium  
ceftropime

1-[[[(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-6,7-dihydro-5*H*-1-pyridinium hydroxide, inner salt, 7*Z*-(*O*-methylxime)  
C<sub>22</sub>H<sub>22</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> 84957-29-9



ciclotropii bromidum  
ciclotropium bromide

(8*r*)-3α-hydroxy-8-isopropyl-1α*H*,5α*H*-tropanium bromide,  
α-phenylcyclopentaneacetate  
C<sub>24</sub>H<sub>36</sub>BrNO<sub>2</sub> 85166-20-7




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


cifostodinum  
cifostodine

cytidine cyclic 2',3'-(hydrogen phosphate)  
 $C_9H_{12}N_3O_7P$  633-90-9




ciglitazonum  
ciglitazone

(±)-5-[p-[(1-methylcyclohexyl)methoxy]benzyl]-2,4-thiazolidinedione  
 $C_{18}H_{23}NO_3S$  74772-77-3



cilastatinum  
cilastatin

(Z)-7-[[*(R)*]-2-amino-2-carboxyethyl]thio]-2-[[*(S)*]-2,2-dimethylcyclopropanecarboxamido]-2-heptenoic acid  
 $C_{15}H_{26}N_2O_5S$  82009-34-5




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


cinexaxadilum  
cinexaxadil

$\alpha$ -[[[(8-acetyl-1,4-benzodioxan-5-yl)oxy]methyl]-4-(3,4,5-trimethoxycinnamoyl)-1-piperazineethanol  
C<sub>29</sub>H<sub>36</sub>N<sub>2</sub>O<sub>9</sub> 69118-25-8




ciprazafonum  
ciprazafone

4'-chloro-2'-(*o*-chlorobenzoyl)-2-(cyclopropylamino)-*N*-methylacetanilide  
C<sub>19</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub> 75616-03-4




ciprofloxacinum  
ciprofloxacine

1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid  
C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub> 85721-33-1



dazopridum  
dazopride

4-amino-5-chloro-*N*-(1,2-diethyl-4-pyrazolidinyl)-*o*-anisamide  
C<sub>15</sub>H<sub>23</sub>ClN<sub>4</sub>O<sub>2</sub> 70181-03-2




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


dembroxolum  
dembroxol

*trans*-4-[(3,5-dibromosalicyl)amino]cyclohexanol  
C<sub>13</sub>H<sub>17</sub>Br<sub>2</sub>NO<sub>2</sub> 83200-09-3




lofopaminum  
lofopamine

(-)-(R)- $\alpha$ -[[[(3,4-dimethoxyphenethyl)amino]methyl]-*p*-hydroxybenzyl] alcohol  
C<sub>18</sub>H<sub>23</sub>NO<sub>4</sub> 71771-90-9




diacereinum  
diacerein

9,10-dihydro-4,5-dihydroxy-9,10-dioxo-2-anthroic acid, diacetate  
C<sub>19</sub>H<sub>12</sub>O<sub>8</sub> 13739-02-1



dicirenonum  
dicirenone

17-hydroxy-3-oxo-17 $\alpha$ -pregn-4-ene-7 $\alpha$ ,21-dicarboxylic acid,  $\gamma$ -lactone, isopropyl ester  
C<sub>26</sub>H<sub>36</sub>O<sub>5</sub> 41020-79-5




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


dilevalolum  
dilevalol

(-)-5-[[1*R*]-1-hydroxy-2-[[[1*R*]-1-methyl-3-phenylpropyl]-  
amino]ethyl]salicylamide  
C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub> 75659-07-3




dopexaminum  
dopexamine

4-[2-[[6-(phenethylamino)hexyl]amino]ethyl]pyrocatechol  
C<sub>22</sub>H<sub>32</sub>N<sub>2</sub>O<sub>2</sub> 86197-47-9




dotarizinum  
dotarizine

1-(diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine  
C<sub>29</sub>H<sub>34</sub>N<sub>2</sub>O<sub>2</sub> 84625-59-2



enalaprilatum  
enalaprilat

1-[*N*-[[*S*]-1-carboxy-3-phenylpropyl]-*L*-alanyl]-*L*-proline  
C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub> 76420-72-9




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


enisoprostum  
enisoprost

{±}-methyl (Z)-7-[(1*R*,2*R*,3*R*)-3-hydroxy-2-[(*E*)-(4*R**S*)-4-hydroxy-4-methyl-1-octenyl]-5-oxocyclopentyl]-4-heptenoate  
C<sub>22</sub>H<sub>36</sub>O<sub>5</sub> 81026-63-3




enprostilum  
enprostil

methyl 7-[(1*R*\*,2*R*\*,3*R*\*)-3-hydroxy-2-[(*E*)-(3*R*\*)-3-hydroxy-4-phenoxy-1-butenyl]-5-oxocyclopentyl]-4,5-heptadienoate  
C<sub>23</sub>H<sub>28</sub>O<sub>6</sub> 73121-56-9




ericololum  
ericolol

{±}-3-[2-[3-(*tert*-butylamino)-2-hydroxypropoxy]-4-chlorophenyl]-2-cyclopenten-1-one  
C<sub>18</sub>H<sub>24</sub>ClNO<sub>3</sub> 85320-67-8



erocainidum  
erocainide

(*E*)-2-(*p*-chlorobenzylidene)cyclohexanone (*E*)-*O*-[3-(diisopropylamino)propyl]oxime  
C<sub>22</sub>H<sub>33</sub>ClN<sub>2</sub>O 85750-38-5




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


esmololum  
esmolol

(+)-methyl *p*-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate  
C<sub>16</sub>H<sub>25</sub>NO<sub>4</sub> 84057-94-3




etersalatum  
etersalate

salicylic acid acetate, ester with  $\beta$ -hydroxy-*p*-acetophenetidide or  
2-(*p*-acetamidophenoxy)ethyl salicylate, acetate (ester)  
C<sub>19</sub>H<sub>19</sub>NO<sub>6</sub> 62992-61-4




etilefrini pivalas  
etilefrine pivalate

( $\pm$ )-*m*-[(ethylamino)-1-hydroxyethyl]phenyl pivalate or ( $\pm$ )- $\alpha$ -[(ethyl-  
amino)methyl]-*m*-hydroxybenzyl alcohol 3-pivalate  
C<sub>15</sub>H<sub>23</sub>NO<sub>3</sub> 85750-39-6




fisalaminum  
fisalamine

5-aminosalicylic acid  
C<sub>7</sub>H<sub>7</sub>NO<sub>3</sub> 89-57-6



florifeninum  
florifenine

2-(1-pyrrolidinyl)ethyl *N*-[7-(trifluoromethyl)-4-quinolyl]anthranilate  
C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> 83863-79-0




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


fluprofyllinum  
fluprofylline

7-[3-[4-(*p*-fluorobenzoyl)piperidino]propyl]theophylline  
C<sub>22</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> 85118-43-0




flusoxololum  
flusoxolol

(*S*)-1-[*p*-[2-[(*p*-fluorophenethyl)oxy]ethoxy]phenoxy]-3-(isopropylamino)-2-propanol  
C<sub>22</sub>H<sub>30</sub>FNO<sub>4</sub> 84057-96-5




flutropii bromidum  
flutropium bromide

(8*r*)-8-(2-fluoroethyl)-3 $\alpha$ -hydroxy-1 $\alpha$ H,5 $\alpha$ H-tropanium bromide, benzilate  
C<sub>24</sub>H<sub>29</sub>BrFNO<sub>3</sub> 63516-07-4



fluzinamidum  
fluzinamide

*N*-methyl-3-[( $\alpha,\alpha,\alpha$ -trifluoro-*m*-tolyl)oxy]-1-azetidincarboxamide  
C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 76263-13-3




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


fosfocreatininum  
fosfocreatinine

(1-methyl-4-oxo-2-imidazolidinylidene)phosphoramidic acid  
C<sub>4</sub>H<sub>8</sub>N<sub>3</sub>O<sub>5</sub>P 5786-71-0



guaimesalum  
guaimesal

(±)-2-(*o*-methoxyphenoxy)-2-methyl-1,3-benzodioxan-4-one  
C<sub>15</sub>H<sub>14</sub>O<sub>5</sub> 81674-79-5




hyalosidasum  
hyalosidase

hyaluronoglucosaminidase or E.C. 3.2.1.35  
37326-33-3


icospiramidum  
icospiramide

(±)-8-[*cis*-4-cyano-4-(*p*-fluorophenyl)cyclohexyl]-1-(*p*-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-3-acetamide  
C<sub>28</sub>H<sub>31</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> 79449-99-3



idebenonum  
idebenone

2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-*p*-benzoquinone  
C<sub>19</sub>H<sub>30</sub>O<sub>5</sub> 58186-27-9




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


imipenemum  
imipenem

(5*R*,6*S*)-3-[[2-(formimidoylamino)ethyl]thio]-6-[[*R*]-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid  
C<sub>12</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>S 64221-86-9




indanidinum  
indanidine

4-(2-imidazolyl-2-ylamino)-2-methyl-2*H*-indazole  
C<sub>11</sub>H<sub>13</sub>N<sub>5</sub> 85392-79-6




indolaprilum  
indolapril

(2*S*,3*aS*,7*aS*)-1-[(*S*)-*N*-[(*S*)-1-carboxy-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester  
C<sub>24</sub>H<sub>34</sub>N<sub>2</sub>O<sub>5</sub> 80876-01-3



iosimidum  
iosimide

*N,N,N',N'',N'''*-hexakis(2-hydroxyethyl)-2,4,6-triiodo-1,3,5-benzenetricarboxamide  
C<sub>21</sub>H<sub>30</sub>I<sub>3</sub>N<sub>3</sub>O<sub>5</sub> 79211-10-2




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


itraconazolum  
itraconazole

(±)-1-*sec*-butyl-4-[*p*-[4-[*p*-[[[2*R*\*,4*S*\*]-2-(2,4-dichlorophenyl)-2-(1*H*-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<sup>2</sup>-1,2,4-triazolin-5-one  
C<sub>35</sub>H<sub>38</sub>Cl<sub>2</sub>N<sub>8</sub>O<sub>4</sub> 84625-61-6




ketotrexatum  
ketotrexate

*N*-[*p*-[[2-(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyloxy)ethyl]amino]benzoyl]-L-glutamic acid  
C<sub>21</sub>H<sub>27</sub>N<sub>7</sub>O<sub>6</sub> 52196-22-2



laurixaminum  
laurixamine

3-(dodecyloxy)propylamine  
C<sub>15</sub>H<sub>33</sub>NO 7617-74-5




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


laurocapramum  
laurocapram

1-dodecylhexahydro-2*H*-azepin-2-one  
C<sub>18</sub>H<sub>35</sub>NO 59227-89-3




lenampicillinum  
lenampicillin

2,3-dihydroxy-2-butenyl (2*S*,5*R*,6*R*)-6-[(*R*)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate, cyclic carbonate  
C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O<sub>7</sub>S 86273-18-9



levocabastinum  
levocabastine

(-)-*trans*-1-[*cis*-4-cyano-4-(*p*-fluorophenyl)cyclohexyl]-3-methyl-4-phenylisonipetric acid  
C<sub>26</sub>H<sub>29</sub>FN<sub>2</sub>O<sub>2</sub> 79516-68-0




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


lisinoprilum  
lisinopril

1-[N<sup>2</sup>-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline  
C<sub>21</sub>H<sub>31</sub>N<sub>3</sub>O<sub>5</sub> 76547-98-3




loxoprofenum  
loxoprofen

(±)-p-[(2-oxocyclopentyl)methyl]hydratropic acid  
C<sub>15</sub>H<sub>18</sub>O<sub>3</sub> 68767-14-6




lufuradomum  
lufuradom

(±)-N-[(8-fluoro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-yl)methyl]-3-furamide  
C<sub>22</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>2</sub> 85118-42-9



meciadanolum  
meciadanol

(2R,3S)-3-methoxy-3',4',5,7-flavantetrol  
C<sub>16</sub>H<sub>16</sub>O<sub>6</sub> 65350-86-9




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


mifentidinum  
mifentidine

*N*-(*p*-imidazol-4-ylphenyl)-*N'*-isopropylformamidine  
C<sub>13</sub>H<sub>16</sub>N<sub>4</sub> 83184-43-4




flavinonum  
flavinone

1,6-dihydro-2-methyl-6-oxo[3,4'-bipyridine]-5-carbonitrile  
C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O 78415-72-2




minocromilum  
minocromil

6-(methylamino)-4-oxo-10-propyl-4*H*-pyrano[3,2-*g*]quinoline-2,8-dicarboxylic acid  
C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>6</sub> 85118-44-1



mioflazinium  
mioflazine

(±)-4-[4,4-bis(*p*-fluorophenyl)butyl]-3-carbamoyl-2',6'-dichloro-1-piperazineacetanilide  
C<sub>29</sub>H<sub>30</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> 79467-23-5




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


nafarelinum  
nafarelin

5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-  
L-leucyl-L-arginyl-L-prolylglycinamide  
C<sub>66</sub>H<sub>83</sub>N<sub>17</sub>O<sub>13</sub> 76932-56-4




naflocortum  
naflocort

9-fluoro-1',4'-dihydro-11 $\beta$ ,21-dihydroxy-2' $\beta$ H-naphtho[2',3',16,17]pregna-1,4-  
diene-3,20-dione  
C<sub>29</sub>H<sub>33</sub>FO<sub>4</sub> 59497-39-1



nafoxadolum  
nafoxadol

5-(2-naphthyl)-6,8-dioxa-3-azabicyclo[3.2.1]octane  
C<sub>15</sub>H<sub>15</sub>NO<sub>2</sub> 84145-90-4




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


nedocromilum  
nedocromil

9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4*H*-pyrano[3,2-*g*]quinoline-2,8-  
dicarboxylic acid  
C<sub>19</sub>H<sub>17</sub>NO<sub>7</sub> 69049-73-6




nefazodonum  
nefazodone

1-[3-[4-(*m*-chlorophenyl)-1-piperazinyl]propyl]-3-ethyl-4-(2-phenoxyethyl)-  
 $\Delta^2$ -1,2,4-triazolin-5-one  
C<sub>25</sub>H<sub>32</sub>ClN<sub>5</sub>O<sub>2</sub> 83366-66-9




nivadipinum  
nivadipine

5-isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(*m*-nitrophenyl)-3,5-  
pyridinedicarboxylate  
C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>6</sub> 75530-68-6



pinadolinum  
pinadoline

1-[(8-chlorodibenz[*b,f*][1,4]oxazepin-10(11*H*)-yl)carbonyl]-2-  
(5-chlorovaleryl)hydrazine  
C<sub>19</sub>H<sub>19</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> 38955-22-5




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


propacetamol  
propacetamol

*N,N*-diethylglycine, ester with 4'-hydroxyacetanilide  
C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub> 66532-85-2




proterguridum  
proterguride

1,1-diethyl-3-(6-propylergolin-8 $\alpha$ -yl)urea  
C<sub>22</sub>H<sub>32</sub>N<sub>4</sub>O 77650-95-4




quinacainolum  
quinacainol

( $\pm$ )-2-*tert*-butyl- $\alpha$ -[2-(4-piperidyl)ethyl]-4-quinolinemethanol  
C<sub>21</sub>H<sub>30</sub>N<sub>2</sub>O 86024-64-8



ropivacainum  
ropivacaine

(-)-1-propyl-2',6'-pipecoloxylidide  
C<sub>17</sub>H<sub>28</sub>N<sub>2</sub>O 84057-95-4




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


tauromustinum  
tauromustine

1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea  
C<sub>7</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub>S 85977-49-7




±-eprofenum  
±-eprofen

(±)-α-methyl-2-phenyl-6-benzothiazoleacetic acid  
C<sub>16</sub>H<sub>13</sub>NO<sub>2</sub>S 85702-89-2




telenzepinum  
telenzepine

4,9-dihydro-3-methyl-4-[(4-methyl-1-piperazinyl)acetyl]-10H-thieno-  
[3,4-b][1,5]benzodiazepin-10-one  
C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>S 80880-90-6



teopranitolium  
teopranitol

1,4:3,6-dianhydro-2-deoxy-2-[[3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxapurin-  
7-yl)propyl]amino]-L-iditol 5-nitrate  
C<sub>16</sub>H<sub>22</sub>N<sub>6</sub>O<sub>7</sub> 81792-35-0




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


teprenonum  
teprenone

6,10,14,18-tetramethyl-5,9,13,17-nonadecatetraen-2-one, mixture of (5*E*,9*E*,13*E*)  
and (5*Z*,9*E*,13*E*) isomers  
 $C_{23}H_{38}O$



terguridum  
terguride

1,1-diethyl-3-(6-methylergolin-8 $\alpha$ -yl)urea  
 $C_{20}H_{28}N_4O$  37686-84-3



teriparatidum  
teriparatide


L-seryl-L-valyl-L-seryl-L-glutamyl-L-isoleucyl-L-glutamyl-L-leucyl-L-methionyl-  
L-histidyl-L-asparaginyll-L-leucylglycyl-L-lysyl-L-histidyl-L-leucyl-L-asparaginyll-  
L-seryl-L-methionyl-L-glutamyl-L-arginyl-L-valyl-L-glutamyl-L-tryptophyl-L-leucyl-  
L-arginyl-L-lysyl-L-lysyl-L-leucyl-L-glutamyl-L-aspartyl-L-valyl-L-histidyl-  
L-asparaginyll-phenyl-L-alanine  
 $C_{181}H_{281}N_{55}O_{51}S_2$  52232-67-4

tilactasum  
tilactase

$\beta$ -D-galactosidase or E C 3.2.1.23  
9031-11-2

timefuronom  
timefurone

4,9-dimethoxy-7-[(methylthio)methyl]-5*H*-furo[3,2-*g*][1]benzopyran-5-one  
 $C_{15}H_{14}O_5S$  76301-19-4




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


tipinastum  
tipinast

3,4-dihydro-6-isobutyl-5-methyl-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid  
C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>S 83153-39-3




tolnapersinum  
tolnapersine

5,6,7,8-tetrahydro-6-(4-*o*-tolyl-1-piperazinyl)-2-naphthol  
C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O 70312-00-4




tosulurum  
tosulur

2-methoxyethyl (*p*-tolylsulfonyl)carbamate  
C<sub>11</sub>H<sub>15</sub>NO<sub>5</sub>S 87051-13-6




triletidum  
triletide

*N*-[*N*-(*N*-acetyl-3-phenyl-L-alanyl)-3-phenyl-L-alanyl]-L-histidine, methyl ester  
C<sub>27</sub>H<sub>31</sub>N<sub>5</sub>O<sub>5</sub> 62087-96-1



troxidum  
troxipide

(±)-3,4,5-trimethoxy-*N*-3-piperidylbenzamide  
C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> 30751-05-4




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


tubulozolum  
tubulozole

ethyl (±)-*cis-p*-[[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl]thio]carbanilate  
C<sub>23</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>4</sub>S 84697-22-3




ufenamatam  
ufenamate

butyl *N*-( $\alpha,\alpha,\alpha$ -trifluoro-*m*-tolyl)anthranilate  
C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 67330-25-0




valproatum seminatricum  
valproate semisodium

sodium hydrogen bis(2-propylvalerate)  
C<sub>16</sub>H<sub>31</sub>NaO<sub>4</sub> 76584-70-8



vinepidinum  
vinepidine

(4'*S*)-4'-deoxyeurocristine  
C<sub>46</sub>H<sub>56</sub>N<sub>4</sub>O<sub>9</sub> 68170-69-4




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number


zinoconazololum  
zinoconazole

5-chloro-2-thienyl imidazol-1-ylmethyl ketone,  
(E)-(2,6-dichlorophenyl)hydrazone  
C<sub>15</sub>H<sub>11</sub>Cl<sub>3</sub>N<sub>4</sub>S 84697-21-2



zuclopenthixolum  
zuclopenthixol

(Z)-4-[3-(2-chlorothioxanthen-9-ylidene)propyl]-1-piperazineethanol  
C<sub>22</sub>H<sub>25</sub>ClN<sub>2</sub>OS 53772-83-1



AMENDMENT  
TO PREVIOUS LISTS

Cumulative List No. 6, 1982

International Nonproprietary Names (INN) for Pharmaceutical Substances:


	<i>delete</i>	<i>insert</i>
p. 40	binodalinum binodaline	binedalinum binedaline
p. 142	furoxicillinum furoxicillin	fumoxicillinum fumoxicillin
p. 167	isodapamidum isodapamide	zidapamidum zidapamide
p. 199	mithramycinum mithramycin	plicamycinum plicamycin
p. 278	stilonii iodidum stilonium iodide	<i>replace CAS reg. no. by: 77257-42-2</i>
p. 300	tiosinaminum tiosinamine	allylthiourea allylthiourea

Vol. 28, No. 9

International Nonproprietary Names (Prop. INN): List 32

p. 18 stilonii iodidum  
stilonium iodide

*complete chemical name with (E), e.g. triethyl[2-[(E)- and  
replace CAS reg. no. and structure by: 77257-42-2*



Vol. 37, No. 2

International Nonproprietary Names (Prop. INN): List 49

p. 10	imidololum imidolol	adimololum adimolol
p. 14	nipradololum nipradolol	nipradilolum nipradilol

## Annex 1

### PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES \*

The following procedure shall be followed by the World Health Organization in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with the World Health Assembly resolution WHA311

1. Proposals for recommended international nonproprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Nonproprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international nonproprietary name is being considered.

A Such notice shall be given by publication in the *Chronicle of the World Health Organization*<sup>1</sup> and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

(i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

- (i) set forth the name under consideration;
- (ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;
- (iii) identify the substance for which a name is being considered;
- (iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;
- (v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.<sup>1</sup>

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.<sup>1</sup>

A. Such objection shall

- (i) identify the person objecting;
- (ii) state his interest in the name;
- (iii) set forth the reasons for his objection to the name proposed

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international nonproprietary name

8. In forwarding a recommended international nonproprietary name to Member States under article 7, the Director-General of the World Health Organization shall

A. request that it be recognized as the nonproprietary name for the substance, and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

\* Text adopted by the Executive Board of WHO in resolution EB15 R7 (*Off. Rec. World Health Org.*, 1955, 60, 3) and amended by the Board in resolution EB43 R9 (*Off. Rec. World Health Org.*, 1969, 173, 10)

<sup>1</sup> The title of this publication was changed to *WHO Chronicle* in January 1959.

### GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological,

pathological or therapeutic suggestion should be avoided.

*These primary principles are to be implemented by using the following secondary principles*

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. "oxacillin" and "oxacillin sodium", "ibufenac" and "ibufenac sodium".

5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ

only in respect of the name of the inactive acid or the inactive base.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7. To facilitate the translation and pronunciation of INN, "f" should be

used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y"; the use of the letters "h" and "k" should be avoided.

8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in INN (see Guiding Principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.<sup>1</sup> Where a stem is shown without any hyphens it may be used anywhere in the name

<i>Latin</i>	<i>English</i>	
-acum	-ac	anti-inflammatory agents of the ibufenac group
-actidum	-actide	synthetic polypeptides with a corticotrophin-like action
-adolum	-adol	} analgesics
-adol-	-adol-	
-astum	-ast	anti-asthmatic, anti-allergic substances not acting primarily as antihistaminic
-astinum	-astine	antihistaminics
-azepamum	-azepam	substances of the diazepam group
-bactamum	-bactam	$\beta$ -lactamase inhibitors
bol	bol	steroids, anabolic
-buzonium	-buzone	anti-inflammatory analgesics of the phenylbutazone group
-cain-	-cain-	antifibrillant substances with local anaesthetic activity
-cainum	-caine	local anaesthetics
cef-	cef-	antibiotics, derivatives of cephalosporanic acid
-cillinum	-cillin	antibiotics, derivatives of 6-aminopenicillanic acid
cort	cort	corticosteroids, except those of the prednisolone group
-dipinum	-dipine	peripheral vasodilators of the nifedipine group
-fibratum	-fibrate	substances of the clofibrate group
-forminum	-formin	hypoglycemics of the phenformin group
gest	gest	steroids, progestogens
gli-	gli-	sulfonamide hypoglycemics
io-	io-	iodine-containing contrast media
-ium	-ium	quaternary ammonium compounds
-metacinum	-metacin	anti-inflammatory substances of the indometacin group
-mycinum	-mycin	antibiotics, produced by <i>Streptomyces</i> strains
-nidazolium	-nidazole	antiprotozoal substances of the metronidazole group
-ololum	-olol	$\beta$ -adrenergic blocking agents of the propranolol group
-oxacinum	-oxacin	antibacterial agents of the nalidix acid group
-pridum	-pride	sulpiride derivatives
-profenum	-profen	anti-inflammatory substances of the ibuprofen group
prost	prost	prostaglandins
-relinum	-relin	hypophyseal hormone release-stimulating peptides
-terolum	-terol	bronchodilators, phenethylamine derivates
-tidinum	-tidine	H <sub>2</sub> -receptor antagonists
-trexatum	-trexate	folic acid antagonists
-verinum	-verine	spasmolytics with a papaverine-like action
vin-	vin-	} vinca type alkaloids
-vin-	-vin-	

<sup>1</sup> A more extensive listing of stems is contained in the working document Pharm S/Nom 15 which is regularly updated and can be requested from Pharmaceuticals, WHO, Geneva

## Annex 2 NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES: TWENTIETH REPORT OF THE WHO EXPERT COMMITTEE

In its twentieth report<sup>1</sup> the WHO Expert Committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures

for selecting, international nonproprietary names (INN) in the light of developments in pharmaceutical compounds in recent years. The most significant recent change has been

the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice in-

volves employing a characteristic "stem" indicative of a common property of the members of a group. The reasons for, and the implications of, the change are fully discussed. Also reported is the intention to change the practice with regard to the nomenclature of individual members of polymeric series.

Other sections of the report concern instructions to be followed by bodies making application for international nonproprietary names, the availability of computer-printed cumulative lists of international nonpro-

prietary names, information supplied by WHO Member States concerning their official use of national or international names for pharmaceutical products, and proposals relative to the withdrawal of international nonproprietary names allocated to substances that are no longer in use.

The official texts relating to the procedures for selecting, and general guidance for devising, international nonproprietary names are reproduced in two annexes to the report. Other annexes give examples of international nonproprietary names that in-

corporate selected stems, the most frequently used initial groups of letters in international nonproprietary names, a historical review of the programme of selecting international nonproprietary names, some useful literature references, and a model of the form to be used in all applications for international nonproprietary names.

<sup>1</sup> WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances* Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 Price Sw fr 6.-.